Search research articles
Contact Us
Filters
Showing results (21-30 of 58) with videos related to
Page
of 6
Sort By:
Oncotarget
|
October 10, 2015
A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL
Eva-Maria Nichols, Rachel Jones, Rachael Watson, et al.
European Journal of Haematology
|
November 15, 2002
Retinoid-induced apoptosis in B-cell chronic lymphocytic leukaemia cells is mediated through caspase-3 activation and is independent of p53, the retinoic acid receptor, and differentiation
Chris Pepper, Khalida Ali, Alun Thomas, et al.
British Journal of Haematology
|
May 25, 2002
Allele and haplotype frequency at human leucocyte antigen class I/II and immunomodulatory cytokine loci in patients with myelodysplasia and acute myeloid leukaemia: in search of an autoimmune aetiology
Duncan Gowans, Alan O'Sullivan, Sara Rollinson, et al.
Blood
|
March 19, 2014
Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia
Elisabeth Walsby, Andrea Buggins, Stephen Devereux, et al.
British Journal of Haematology
|
November 9, 2019
Increased frequency of CD4<sup>+</sup> PD-1<sup>+</sup> HLA-DR<sup>+</sup> T cells is associated with disease progression in CLL
Lauren Elston, Chris Fegan, Robert Hills, et al.
Cancer Research
|
June 24, 2011
A novel tumor antigen derived from enhanced degradation of bax protein in human cancers
Cláudia Trindade Nunes, Kelly L Miners, Garry Dolton, et al.
Molecular Cancer Therapeutics
|
June 3, 2010
The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib
Elisabeth J Walsby, Guy Pratt, Saman Hewamana, et al.
Chemmedchem
|
November 26, 2008
Natural-product-like spiroketals and fused bicyclic acetals as potential therapeutic agents for B-cell chronic lymphocytic leukaemia
Lech-Gustav Milroy, Giovanna Zinzalla, François Loiseau, et al.
British Journal of Haematology
|
May 28, 2008
Highly purified CD38 sub-populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38 sub-populations derived from the same chronic lymphocytic leukaemia patient
Thet Thet Lin, Saman Hewamana, Rachel Ward, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2009
Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia
Saman Hewamana, Thet Thet Lin, Clare Rowntree, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 58) with videos related to
Sort By:
Page
of 6
Oncotarget
|
October 10, 2015
A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL
Eva-Maria Nichols, Rachel Jones, Rachael Watson, et al.
European Journal of Haematology
|
November 15, 2002
Retinoid-induced apoptosis in B-cell chronic lymphocytic leukaemia cells is mediated through caspase-3 activation and is independent of p53, the retinoic acid receptor, and differentiation
Chris Pepper, Khalida Ali, Alun Thomas, et al.
British Journal of Haematology
|
May 25, 2002
Allele and haplotype frequency at human leucocyte antigen class I/II and immunomodulatory cytokine loci in patients with myelodysplasia and acute myeloid leukaemia: in search of an autoimmune aetiology
Duncan Gowans, Alan O'Sullivan, Sara Rollinson, et al.
Blood
|
March 19, 2014
Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia
Elisabeth Walsby, Andrea Buggins, Stephen Devereux, et al.
British Journal of Haematology
|
November 9, 2019
Increased frequency of CD4<sup>+</sup> PD-1<sup>+</sup> HLA-DR<sup>+</sup> T cells is associated with disease progression in CLL
Lauren Elston, Chris Fegan, Robert Hills, et al.
Cancer Research
|
June 24, 2011
A novel tumor antigen derived from enhanced degradation of bax protein in human cancers
Cláudia Trindade Nunes, Kelly L Miners, Garry Dolton, et al.
Molecular Cancer Therapeutics
|
June 3, 2010
The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib
Elisabeth J Walsby, Guy Pratt, Saman Hewamana, et al.
Chemmedchem
|
November 26, 2008
Natural-product-like spiroketals and fused bicyclic acetals as potential therapeutic agents for B-cell chronic lymphocytic leukaemia
Lech-Gustav Milroy, Giovanna Zinzalla, François Loiseau, et al.
British Journal of Haematology
|
May 28, 2008
Highly purified CD38 sub-populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38 sub-populations derived from the same chronic lymphocytic leukaemia patient
Thet Thet Lin, Saman Hewamana, Rachel Ward, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2009
Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia
Saman Hewamana, Thet Thet Lin, Clare Rowntree, et al.
Page
of 6